BEVERLY, Mass.--(BUSINESS WIRE)--HepatoChem, Inc. has announced that it has been awarded a $330,000 loan from the Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the State’s $1 billion Life Sciences Initiative (MLSC). HepatoChem is an early stage life science company with a game changing, proprietary chemistry platform that enables fast and cost effective metabolite production from bioactive small molecules. The HepatoChem technology enables assessment of critical metabolite and toxicity issues relatively early in the R&D continuum, reducing the risk of failure in clinical development of drug candidates.
